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Different genotypes in a large Italian family with recurrent
hereditary fructose intolerance
Anna Caciottia, Maria Alice Donatia, Andrea Adamib, Renzo Guerrinia,
Enrico Zammarchia and Amelia Morronea
Objectives Hereditary fructose intolerance is caused by a
deficiency of the aldolase B enzyme, which is expressed in
the liver, small intestine and kidneys. Patients usually show
a marked aversion to fruits and sweets; if, however, it is not
diagnosed, persistent or incidental ingestion of fructose
might be lethal. Our paper aims at improving the clinical
and molecular characterizations of these patients, to avoid
dangerous misdiagnoses.
Methods Here we report the molecular results in an Italian
cohort: on the occurrence of aldolase B mutations and, in
particular, on the clinical and molecular characterization of
a large family with recurrent hereditary fructose
intolerance.
Results Patients included in our cohort showed the three
most common mutations (p.A150P, p.A175D and p.N335K).
Such molecular tests were enough to cover all the mutated
alleles of hereditary fructose intolerance found in our
patients. The allele frequencies of hereditary fructose
intolerance mutations detected were 69.2% for p.A150P,
23.1% for p.A175D and 7.7% for p.N335K. The proband
of the family with recurrence of the disease was
heterozygous for the known p.A150P and p.A175D mutated
alleles of the aldolase B gene. Molecular characterization
of at-risk family members also identified the p.N335K
mutation. In addition, the oldest affected patients exhibited
mild clinical impairment.
Conclusions Our results indicate that the diagnosis of
hereditary fructose intolerance can be complicated by
clinical and genetic intrafamilial variability. A knowledge
of the clinical and geographical history of each family
member is thus essential, to reduce potentially lethal
misdiagnoses and to facilitate such patients to receive
appropriate genetic counselling. Eur J Gastroenterol
Hepatol 20:118–121 c 2008 Wolters Kluwer Health |
Lippincott Williams & Wilkins.
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Introduction
Hereditary fructose intolerance (HFI; Online Mendelian
Inheritance in Man +229600), which is caused by the
absence or reduction of the aldolase (EC 4.1.2.13) enzyme,
B isoform (ALDOB), has an estimated frequency of 1 in
20000 births [1]. Despite eating habits that include
increased sugar consumption in industrialized countries,
patients’ distinct aversion to fruit and sweets is the major
reason for underdiagnoses of HFI [1,2]. Untreated
patients, being unable to assimilate dietary fructose, can
develop a broad range of gastrointestinal symptoms, lactic
acidosis and hypoglycaemia. Persistent ingestion of fruc-
tose and related sugars can lead to severe liver and kidney
damage, seizures, coma and risk of death [1].
The human ALDOB gene has been cloned and character-
ized: the gene consists of nine exons encoding a
polypeptide containing 364 amino acids [3]. So far, about
35 mutations in the ALDOB gene have been reported
[4,5]. The most common ALDOB mutations, p.A150P,
p.A175D and p.N335K, account for about 72–76% of HFI
mutated alleles worldwide [4–6]. The p.A150P mutation
has a greater frequency in Northern Europe, whereas the
p.A175D mutation is predicted to be more frequent in
Southern Europe, and the p.N335K in Central and
Eastern Europe [5,7]. These general population studies
included the Italian population. In addition, Italian HFI
patients have been analysed as an exclusive group [8,9].
The estimated frequencies of the p.A150P and p.A175D
mutated alleles in Italy are reported to be about 50 and
30%, respectively [8,9]. Seven mutations have, however,
been proposed to account for about 95% of Italian ALDOB
mutated alleles [10].
Given the high prevalence of a small number of ALDOB
mutations, a rational mutation-screening programme
could be introduced. It seems likely that the frequency
of HFI has been underestimated: hence, such a
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programme could have a dramatic impact for potential
patients, as dietary treatment can prevent this potentially
lethal disease [5].
To increase the number of characterized HFI patients
and to ascertain the prevalence of each mutation in the
Italian population better, we report the allele frequencies
of HFI mutations that were detected in the ALDOB gene
of 13 index patients. This HFI cohort includes index
patients from a large Italian family with recurrent HFI
and atypical molecular characterization due to the
presence of the three common ALDOB mutations.
Methods
Patients
The clinical presentations of the HFI patients, belonging
to the large Italian family here reported, are summarized
in Table 1. The eight additional unrelated Italian
patients, who were included in our cohort, presented
classic HFI phenotypes.
Genomic DNA isolation and analysis
Consent statements for genetic analysis were obtained
from all patients. Genomic DNA was obtained from
patients’ lymphocytes using a commercial DNA-extrac-
tion kit (Qiagen, Hilden, Germany). The oligonucleo-
tides and the PCR-amplifying conditions have been
described previously [11]. The three most common
ALDOB mutations were screened. Three ALDOB frag-
ments, encompassing exons 5 and 9 and containing the
p.A150P, p.A175D and p.N335K mutations, were ampli-
fied and directly sequenced on both strands.
The PCR products were checked on a 1.5% agarose gel,
and were excised and purified using Nucleospin Extract
kit (Macherey-Nagel, Du¨ren, Germany).
Sequencing reactions were performed using the ABI
PRISM 310 Genetic Analyzer (Applied Biosystems,
Foster City, California, USA), as recommended by the
manufacturer. The nomenclature of the genetic lesions of
the ALDOB gene is as designated previously [12–14].
The mutation frequencies of the three common HFI
mutations, which refer to the index patients here
analysed, are reported.
Results
Molecular analysis of HFI index patients included in our
cohort showed the three most common mutated alleles
(resulting in p.A150P, p.A175D and p.N335K mutations).
The allele frequencies of the HFI mutations detected
were 69.2% for p.A150P, 23.1% for p.A175D and 7.7% for
p.N335K.
As part of our cohort, the index patients of a large Italian
family with recurrent HFI were further investigated at
clinical and molecular levels (Table 1, Fig. 1). The
proband (patient III:6) presented at 13 months with
hypoglycaemic seizures and hypotonia, after the unwilling
intake of a fruit shake at kindergarten. HFI was
suspected because of mild metabolic acidosis, hepatome-
galy, a rapid rescue of the patient’s condition after the
infusion of glucosaline solutions and her aversion to
sweet-tasting foods. To provide a confirmatory diagnosis,
molecular analysis of the most common ALDOB gene
mutations was opted for, and the p.A150P and p.A175D
mutated alleles were detected. Two of the proband’s
cousins (patients III:1 and III:2) presented with a strong
aversion to foods containing fructose as the only indicator
of the disease. Mutation analysis again detected the
p.A150P and p.A175D mutations in both patients,
although patients II:6 and II:20 were reported to be
nonconsanguineous.
Aversion to sweet-tasting foods and abdominal pain also
prompted patient III:5 to undergo ALDOB-gene mole-
cular investigation. Interestingly, the p.N335K mutation
was also detected along with the p.A150P mutation.
Table 1 Synopses of the main characteristics of the members of the large family reported here
Patient III:6 proband III:7 III:1 III:2 III:5
Age 3 years 2 years 23 years 21 years 18 months
Origin Northern Italy Northern Italy Northern Italy Northern Italy Northern Italy
Growth Normal At the 10th centile Normal Normal Normal
Metabolic presentationa Hypoglycaemia, mild
metabolic acidosis and
vomiting
Absent Absent Vomiting Absent
Gastrointestinal
abnormalities
Mild hepatomegaly and
hepatic steatosis
Mild hepatomegaly and
hepatic steatosis
Normal Normal Hepatomegaly and
abdominal cramps in
the preceding months
Laboratory findings Transient hyper
transaminasaemia
Transient hyper
transaminasaemia
Normal Normal Transient hyper trans-
aminasaemia at 11 months
Crisisa Hypoglycaemic seizures
at 13 months
No, diagnosis at birth Lipothymia at 19 years No No
Aversion to any source
of fructose
Yes No fructose ingestion Yes Yes Yes
Therapy Vitamin C, no fructose
ingestion
Vitamin C, no fructose
ingestion
Vitamin C, no fructose
ingestion
Vitamin C, no fructose
ingestion
No fructose ingestion
aWhen presenting with a crisis, symptoms have followed the ingestion of sweets and/or fruit.
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Discussion
Deficient activity of ALDOB results in the accumulation
of fructose 1-phosphate, which can be particularly toxic
in early life [1], cause severe liver disease and, if
undiagnosed, can lead to death [15].
It has been suggested that establishing the prevalence of
ALDOB-gene mutations is a premise for rational mole-
cular analyses in patients with suspected HFI, and for
the introduction of a screening programme for newborn
babies [5]. Molecular analyses also replace invasive
diagnostic procedures such as the intravenous fructose
load or enzyme assays that are performed on tissue biopsy
samples [1]. A method that uses denaturing high-
pressure liquid chromatography technology has been
proposed for use in screening programmes for newborn
infants [5]; however, projects in this field might be
complicated by the occurrence of private or rare HFI
mutations.
Our molecular results showed a distribution of the
p.A150P mutation that was relatively closer to that of
the pan-European population [16], than to that of Italian
patients [6,9]. The p.A150P mutation has been described
as being more frequent in North Europe than in Italy;
however, a frequent mutation reported in the Italian
population (c.865delC) has been predicted to be limited
to Sicily [6]. The inclusion of Sicilian patients in a HFI
survey can thus create an imbalance in the estimates of
the prevalence of ALDOB mutations in our country.
As predicted [6,9], the frequency of the p.A175D
mutation was particularly high, compared with recently
reported frequencies in Central Europe (15%) or Spain
(15.8%) [5,16]. The p.N335K mutation has probably
spread from Eastern and/or Central Europe [4,7]. This
mutated allele, however, also proved to be relatively
common in Italy, with a frequency close to that in Central
Europe [5,16].
A relationship between clinical symptoms and genotype
has not been demonstrated [17]. As the severity of the
disease might vary and as affected patients often impose
fructose restrictions on themselves, adult patients might
be symptom free. Patient III:7, however, despite having
the same genotype as patients III:1 and III:2, and despite
having avoided fructose from birth, exhibited hepatome-
galy and mild steatosis; so did her sister (patient III:6),
suggesting that follow-up through adulthood might be
essential to assess the outcome of the disease. It is thus
likely that the young patients reported herein will show
an improvement in their clinical presentations as they
age, like their older relatives (patients III:1 and III:2). In
addition, we stress the consequences of a spread, and
correct genetic counselling for the diagnoses of patients
III:1 and III:2, who were essentially free of symptoms.
Interestingly, our report showed three independently
segregating alleles within a family unit. Therefore,
clinicians should ideally perform molecular assays of at
least the three common ALDOB mutations. This might
avoid dangerous misdiagnoses, and allow for the early
introduction of a diet eliminating fructose-containing
foods and for the provision of oral vitamin C supplements
to offset the imbalances that a diet without fruit might
entail [18]. Large population screening has previously
demonstrated that HFI patients are heterozygous for at
least one of those three mutations (mutated allele
frequencies 94%) [5]; despite this, seven mutations are
necessary to achieve the 95% prevalence of HFI alleles
in Italian patients [10]. Therefore, the negative results
of the molecular tests performed for the three most
Fig. 1
I:1
II:1 II:2 II:3 II:4
III:1 III:2 III:4 III:3 III:4 III:5 III:6 III:7
II:5 II:6 II:7 II:8 II:9 II:10 II:11 II:12 II:13 II:14 II:15 II:16 II:17 II:18 II:19 II:20
I:2 I:3 I:4 I:5 I:6 I:7
Family pedigree. The proband is indicated by an arrow. Horizontal lines indicate the p.A150P mutation; vertical lines indicate the p.N335K mutation;
the black filling represents the p.A175D mutated allele.
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common mutations do not exclude a positive diagnosis.
In addition, heterozygous patients should be further
investigated at the molecular level.
In conclusion, our data underline the relevance of a
critical approach to the molecular analysis of common,
and possible new, ALDOB mutations. This information
could be useful to screen the ALDOB gene more carefully
in suspected patients (i.e. those at risk), starting from the
numerous parents of the large family here reported. A
careful clinical and molecular diagnosis can be particularly
useful in genetic counselling concerning newborn babies
in affected families, as a very simple dietary therapy can
prevent potentially serious damage caused by the disease.
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